Warning message

You must login or register to view this form.

safescimet course 1.2 - Drug Safety of Stem Cells and other Novel Therapeutics

This course will introduce the emerging area of the safety science of the therapeuticapplication of stem cells, and will address all the key issues that need to be considered by developers of these therapies, including academics and the pharmaceutical/biotech industry, as well as the important area of regulation. Other new areas of therapy will also be considered, such as genetically-engineered cells. The use of stem cells in the screening of conventional drugs for efficacy and particularly safety will also be investigated. UK and European leaders in these fields, from Industry, Academia and the Regulatory Agencies, will contribute teaching sessions in a small, informal and interactive learning environment.

Key questions addressed by the course

  • Therapeutic treatment of diseases via novel therapeutics as adult and embryonal stem cells, induced pluripotent stem cells, genetically engineered cells, siRNA / RNAi and exon-skipping oligonucleotides
  • Basic biology of stem cells and molecular therapies
  • Drug safety aspects of novel therapeutic approaches – the key issues
  • Regulatory requirements for adult and embryonal stem cells and novel therapies
  • Use of stem cells in safety assessment
Location 
Konstanz, Germany

On-site course dates

5 February 2018 to 8 February 2018
Course leader 
Prof B Kevin Park
Dr Chris Goldring
Dr Jacqueline Piner
Couse certificate 
CPD, ECTS, MSc
Course fees 
  • Company - 2.500 EUR
  • Small and medium companies (up to 250 employees) - 1.250 EUR
  • Regulatory authorities (government) - 1.250 EUR
  • Academic institutions (universities) - 500 EUR